A clinicopathological approach to the diagnosis of dementia

FM Elahi, BL Miller - Nature Reviews Neurology, 2017 - nature.com
The most definitive classification systems for dementia are based on the underlying
pathology which, in turn, is categorized largely according to the observed accumulation of …

Depression in neurodegenerative diseases: Common mechanisms and current treatment options

CPC Galts, LEB Bettio, DC Jewett, CC Yang… - Neuroscience & …, 2019 - Elsevier
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder and a major
cause of disability worldwide. This neurological condition is commonly associated with …

IL-1β and TNF-α play an important role in modulating the risk of periodontitis and Alzheimer's disease

RPH Wang, J Huang, KWY Chan, WK Leung… - Journal of …, 2023 - Springer
Background Systemic activation of the immune system can exert detrimental effects on the
central nervous system. Periodontitis, a chronic disease of the oral cavity, is a common …

[HTML][HTML] Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

KL Lanctôt, J Amatniek, S Ancoli-Israel… - Alzheimer's & Dementia …, 2017 - Elsevier
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing
substantial distress for both people with dementia and their caregivers, and contributing to …

[HTML][HTML] Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?

C Laurent, L Buée, D Blum - Biomedical journal, 2018 - Elsevier
Alzheimer's Disease (AD) is a chronic neurodegenerative disorder and the most common
type of dementia (60–80% of cases). In 2016, nearly 44 million people were affected by AD …

[HTML][HTML] The role of serotonin within the microbiota-gut-brain axis in the development of Alzheimer's disease: A narrative review

E Aaldijk, Y Vermeiren - Ageing Research Reviews, 2022 - Elsevier
Alzheimer's disease (AD) is the most common cause of dementia, accounting for more than
50 million patients worldwide. Current evidence suggests the exact mechanism behind this …

Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs

RR Ramsay, KF Tipton - Molecules, 2017 - mdpi.com
The actions of many drugs involve enzyme inhibition. This is exemplified by the inhibitors of
monoamine oxidases (MAO) and the cholinsterases (ChE) that have been used for several …

[HTML][HTML] Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing

IF Orlando, JM Shine, TW Robbins, JB Rowe… - Neuroscience & …, 2023 - Elsevier
Noradrenergic and cholinergic systems are among the most vulnerable brain systems in
neuropsychiatric diseases of ageing, including Alzheimer's disease, Parkinson's disease …

Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease

SC Kelly, B He, SE Perez, SD Ginsberg… - Acta neuropathologica …, 2017 - Springer
A major feature of Alzheimer's disease (AD) is the loss of noradrenergic locus coeruleus
(LC) projection neurons that mediate attention, memory, and arousal. However, the extent to …

Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies

G Šimić, M Babić Leko, S Wray, C Harrington, I Delalle… - Biomolecules, 2016 - mdpi.com
Abnormal deposition of misprocessed and aggregated proteins is a common final pathway
of most neurodegenerative diseases, including Alzheimer's disease (AD). AD is …